167 related articles for article (PubMed ID: 29377515)
21. Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
Lalezari J; Sullivan JG; Varunok P; Galen E; Kowdley KV; Rustgi V; Aguilar H; Felizarta F; McGovern B; King M; Polepally AR; Cohen DE
J Hepatol; 2015 Aug; 63(2):364-9. PubMed ID: 25839406
[TBL] [Abstract][Full Text] [Related]
22. Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.
Chan HL; Tsang OT; Hui YT; Fung J; Lui GC; Lai CL; Wong GL; Chan KH; But DY; Lai MS; Lao WC; Chan CK; Lam YS; Seto WK; Li C; Yuen MF; Wong VW
J Gastroenterol Hepatol; 2017 Jun; 32(6):1230-1233. PubMed ID: 27869328
[TBL] [Abstract][Full Text] [Related]
23. Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.
Poordad F; Nelson DR; Feld JJ; Fried MW; Wedemeyer H; Larsen L; Cohen DE; Cohen E; Mobashery N; Tatsch F; Foster GR
J Hepatol; 2017 Oct; 67(4):700-707. PubMed ID: 28645740
[TBL] [Abstract][Full Text] [Related]
24. Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
Tronina O; Durlik M; Wawrzynowicz-Syczewska M; Buivydiene A; Katzarov K; Kupcinskas L; Tolmane I; Karpińska E; Pisula A; Karwowska KM; Bolewska B; Jabłkowski M; Rostkowska K; Jakutiene J; Simonova M; Flisiak R
Ann Transplant; 2017 Apr; 22():199-207. PubMed ID: 28386057
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
Pockros PJ; Reddy KR; Mantry PS; Cohen E; Bennett M; Sulkowski MS; Bernstein DE; Cohen DE; Shulman NS; Wang D; Khatri A; Abunimeh M; Podsadecki T; Lawitz E
Gastroenterology; 2016 Jun; 150(7):1590-1598. PubMed ID: 26976799
[TBL] [Abstract][Full Text] [Related]
26. Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice.
Pineda JA; Rivero-Juárez A; de Los Santos I; Collado A; Merino D; Morano-Amado LE; Ríos MJ; Pérez-Pérez M; Téllez F; Palacios R; Pérez AB; Mancebo M; Rivero A; Macías J
HIV Clin Trials; 2018 Feb; 19(1):23-30. PubMed ID: 29447085
[TBL] [Abstract][Full Text] [Related]
27. A Case of Acute Liver Failure during Ritonavir-Boosted Paritaprevir, Ombitasvir and Dasabuvir Therapy in a Patient with HCV Genotype 1b Cirrhosis.
Masetti M; Magalotti D; Martino E; Andreone P; Scuteri A; Zoli M
J Gastrointestin Liver Dis; 2016 Dec; 25(4):559-561. PubMed ID: 27981315
[TBL] [Abstract][Full Text] [Related]
28. Potential drug-drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir ± DASABUVIR ± ribavirin in clinical practice.
González-Colominas E; Londoño MC; Morillas RM; Torras X; Mojal S; Lens S; López D; Gallego A; Mariño Z; Ardèvol M; Pagès N; Solà R; Carrión JA
J Gastroenterol Hepatol; 2018 May; 33(5):1100-1107. PubMed ID: 28994141
[TBL] [Abstract][Full Text] [Related]
29. Working together to tackle HCV infection: ombitasvir/paritaprevir/ritonavir and dasabuvir combination.
Gamal N; Andreone P
Drugs Today (Barc); 2015 May; 51(5):303-14. PubMed ID: 26097903
[TBL] [Abstract][Full Text] [Related]
30. Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy.
Liu CH; Sun HY; Hsieh SM; Liu WC; Sheng WH; Liu CJ; Su TH; Tseng TC; Chen PJ; Hung CC; Kao JH
J Viral Hepat; 2021 Jun; 28(6):887-896. PubMed ID: 33759290
[TBL] [Abstract][Full Text] [Related]
31. Pharmacokinetic Evaluation of Darunavir Administered Once or Twice Daily in Combination with Ritonavir or the Three-Direct-Acting Antiviral Regimen of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults Coinfected with Hepatitis C and Human Immunodeficiency Viruses.
King JR; Khatri A; Trinh R; Viani RM; Ding B; Zha J; Menon R
Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27919899
[TBL] [Abstract][Full Text] [Related]
32. Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4.
Abad S; Vega A; Hernández E; Mérida E; de Sequera P; Albalate M; Macías N; Milla M; López-Gómez JM
Am J Nephrol; 2017; 45(3):267-272. PubMed ID: 28166520
[TBL] [Abstract][Full Text] [Related]
33. Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.
Polepally AR; Badri PS; Eckert D; Mensing S; Menon RM
Eur J Drug Metab Pharmacokinet; 2017 Apr; 42(2):333-339. PubMed ID: 27165046
[TBL] [Abstract][Full Text] [Related]
34. Real-life results of treatment with ombitasvir, paritaprevir, dasabuvir, and ritonavir combination in patients with chronic renal failure infected with HCV in Turkey.
Yaraş S; Üçbilek E; Özdoğan O; Ateş F; Altıntaş E; Sezgin O
Turk J Gastroenterol; 2019 Apr; 30(4):331-335. PubMed ID: 30666967
[TBL] [Abstract][Full Text] [Related]
35. Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.
Chen CH; Chen CH; Lin CL; Lin CY; Hu TH; Tung SY; Hsieh SY; Lu SN; Chien RN; Hung CH; Sheen IS
Sci Rep; 2019 May; 9(1):7086. PubMed ID: 31068655
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports.
Ponziani FR; Siciliano M; Lionetti R; Pasquazzi C; Gianserra L; D'Offizi G; Gasbarrini A; Pompili M
Am J Kidney Dis; 2017 Aug; 70(2):297-300. PubMed ID: 28258770
[TBL] [Abstract][Full Text] [Related]
37. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
Menon RM; Badri PS; Wang T; Polepally AR; Zha J; Khatri A; Wang H; Hu B; Coakley EP; Podsadecki TJ; Awni WM; Dutta S
J Hepatol; 2015 Jul; 63(1):20-9. PubMed ID: 25646891
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney disease.
Mekky MA; Abdel-Malek MO; Osman HA; Abdel-Aziz EM; Hashim AA; Hetta HF; Morsy KH
Clin Res Hepatol Gastroenterol; 2019 Feb; 43(1):82-87. PubMed ID: 30166253
[TBL] [Abstract][Full Text] [Related]
39. Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.
Steiner S; Bucsics T; Schwabl P; Mandorfer M; Scheiner B; Aichelburg MC; Grabmeier-Pfistershammer K; Ferenci P; Trauner M; Peck-Radosavljevic M; Reiberger T
Wien Klin Wochenschr; 2017 Aug; 129(15-16):517-526. PubMed ID: 28130599
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences.
Örmeci N; Sezgin O; Karaali R; Aygen B; Turan D; Yaras S; Erdem İ; Yildiz O; Karakaya F; Ateş K; Asiller ÖÖ
Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):534-539. PubMed ID: 30672829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]